Endo Agrees to Additional Stay of FDA Litigation Following FDA's Commitment to Use Best Efforts ... BioSpace (press release) (blog) In August 2018, an outsourcing facility announced it would commence bulk compounding of vasopressin and intervened in the litigation.

Endo once more agrees to delay FDA litigation Philadelphia Business Journal The lawsuit alleges the FDA's "interim policy" on compounding using bulk drug substances under Section 503 B of the Drug Quality and Security Act of ... Endo puts Vasostrict case against US FDA on hold - Reuters Full Coverage